CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy CEO, Pres, CFO, Treas & Secy bought 25,000 shares at $0.90 ($22,380)
- 4 Open-market buy Director bought 5,983 shares at $0.80 ($4,786)
- 4 Grant or award Director acquired 4,288,624 shares (grant or award)
- 4 Open-market buy Director bought 19,390 shares at an average $0.75 ($14,560)
- 4 Open-market buy Director bought 32,112 shares at an average $0.71 ($22,691)
- 4 Open-market buy Director bought 13,015 shares at an average $0.68 ($8,828)
- 4 Open-market buy Director bought 3,100 shares at an average $0.69 ($2,131)
- 4 Open-market buy Director bought 8,000 shares at $0.68 ($5,440)
- 4 Open-market buy Director bought 6,665 shares at an average $0.71 ($4,709)
- 4 Open-market buy Director bought 8,845 shares at an average $0.71 ($6,275)
- 4 Open-market buy Director bought 17,781 shares at an average $0.62 ($11,082)
- 4 Open-market buy Director bought 17,189 shares at $0.59 ($10,142)
- 4 Grant or award Director acquired 4,288,624 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Open-market buy Director bought 18,354 shares at an average $0.53 ($9,651)
- 4 Open-market buy Director bought 4,713 shares at an average $0.65 ($3,075)
- 4 Open-market buy Director bought 15,000 shares at $0.68 ($10,251)
Page 11 of 16 · 305 filings